Osteosynthesis-associated infection of the lower limbs by multidrug-resistant and extensively drug-resistant Gram-negative bacteria: a multicentre cohort study

Author:

Giannitsioti Efthymia,Salles Mauro JoséORCID,Mavrogenis Andreas,Rodriguez-Pardo Dolors,Los-Arcos Ibai,Ribera Alba,Ariza Javier,del Toro María Dolores,Nguyen Sophie,Senneville Eric,Bonnet Eric,Chan Monica,Pasticci Maria BrunaORCID,Petersdorf Sabine,Benito NatividadORCID,O' Connell NualaORCID,Blanco García Antonio,Skaliczki GáborORCID,Tattevin Pierre,Kocak Tufan Zeliha,Pantazis NikolaosORCID,Megaloikonomos Panayiotis D.ORCID,Papagelopoulos Panayiotis,Soriano AlejandroORCID,Papadopoulos Antonios,

Abstract

Abstract. Purpose: The purpose of this study was the clinical and therapeutic assessment of lower-limb osteosynthesis-associated infection (OAI) by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacteria (GNB), which have been poorly studied to date. Methods: A prospective multicentre observational study was conducted on behalf of ESGIAI (the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group on Implant-Associated Infections). Factors associated with remission of the infection were evaluated by multivariate and Cox regression analysis for a 24-month follow-up period. Results: Patients (n=57) had a history of trauma (87.7 %), tumour resection (7 %) and other bone lesions (5.3 %). Pathogens included Escherichia coli (n=16), Pseudomonas aeruginosa (n=14; XDR 50 %), Klebsiella spp. (n=7), Enterobacter spp. (n=9), Acinetobacter spp. (n=5), Proteus mirabilis (n=3), Serratia marcescens (n=2) and Stenotrophomonas maltophilia (n=1). The prevalence of ESBL (extended-spectrum β-lactamase), fluoroquinolone and carbapenem resistance were 71.9 %, 59.6 % and 17.5 % respectively. Most patients (n=37; 64.9 %) were treated with a combination including carbapenems (n=32) and colistin (n=11) for a mean of 63.3 d. Implant retention with debridement occurred in early OAI (66.7 %), whereas the infected device was removed in late OAI (70.4 %) (p=0.008). OAI remission was achieved in 29 cases (50.9 %). The type of surgery, antimicrobial resistance and duration of treatment did not significantly influence the outcome. Independent predictors of the failure to eradicate OAI were age >60 years (hazard ratio, HR, of 3.875; 95 % confidence interval, CI95 %, of 1.540–9.752; p=0.004) and multiple surgeries for OAI (HR of 2.822; CI95 % of 1.144–6.963; p=0.024). Conclusions: Only half of the MDR/XDR GNB OAI cases treated by antimicrobials and surgery had a successful outcome. Advanced age and multiple surgeries hampered the eradication of OAI. Optimal therapeutic options remain a challenge.

Publisher

Copernicus GmbH

Subject

Infectious Diseases,Orthopedics and Sports Medicine,Surgery

Reference32 articles.

1. Benito, N., Franco, M., Ribera, A., Soriano, A., Rodriguez-Pardo, D., Sorlí, L., Fresco, G., Fernández-Sampedro, M., Dolores Del Toro, M., Guío, L., Sánchez-Rivas, E., Bahamonde, A., Riera, M., Esteban, J., Baraia-Etxaburu, J. M., Martínez-Alvarez, J., Jover-Sáenz, A., Dueñas, C., Ramos, A., Sobrino, B., Euba, G., Morata, L., Pigrau, C., Coll, P., Mur, I., Ariza, J., and REIPI (Spanish Network for Research in Infectious Disease) Group for the Study of Prosthetic Joint Infections: Time trends in the aetiology of prosthetic joint infections: a multicenter cohort study, Clin. Microbiol. Infect., 732, e1–732.e8, https://doi.org/10.1016/j.cmi.2016.05.004, 2016.

2. Brouqui, P., Rousseau, M. C., Stein, A., Drancourt, M., and Raoult, D.: Treatment of Pseudomonas aeruginosa-infected orthopedic prostheses with ceftazidime ciprofloxacin antibiotic combination, Antimicrob. Agents Chemother., 39, 2423–2425, https://doi.org/10.1128/AAC.39.11.2423, 1995.

3. Corvec, S., Furustrand Tafin, U., Betrisey, B., Borens, O., and Trampuz, A.: Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model, Antimicrob. Agents Chemother., 57, 1421–1427, https://doi.org/10.1128/AAC.01718-12, 2013.

4. European Committee on Antimicrobial Susceptibility Testing (EUCAST): recommendations, http://www.eucast.org/clinical_breakpoint/, last access: 1 January 2022.

5. Glaudemans, A. W. J. M., Jutte, P. C., Cataldo, M. A., Cassar-Pullicino, V., Gheysens, O., Borens, O., Trampuz, A., Wörtler, K., Petrosillo, N., Winkler, H., Signore, A., and Sconfienza, L. M.: Consensus document for the diagnosis of peripheral bone infection in adults: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement), Eur. J. Nucl. Med. Molec. Imaging, 46, 957–970, https://doi.org/10.1007/s00259-019-4262-x, 2019.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3